seguimiento ecográfico de pacientes con carcinoma papilar de tiroides

Recommended ultrasound follow-up for surgically treated papillary thyroid carcinoma (PTC) patients at intermediate-low risk (10-15%) who have received radioactive iodine (RAI) therapy involves a risk-tailored, dynamic approach combining serum thyroglobulin (Tg) measurement with selective neck ultrasound imaging.

According to UK NICE NG230 guidance, for patients who have had total or completion thyroidectomy and RAI, an intermediate risk (often considered medium risk) patient—defined by thyroglobulin levels between 0.2 and 1.0 μg/L, or stimulated Tg between 1 and 10 μg/L—should have clinical follow-up at least annually for 5 to 10 years with thyroglobulin testing, and ultrasound imaging should be performed if clinically indicated (for example, if thyroglobulin levels rise or there is suspicion on examination) rather than routinely at every visit NICE NG230.

Initial ultrasound may be considered at 6 to 12 months after surgery and RAI if there are no contraindications or excellent response, then further imaging guided by dynamic risk stratification and biochemical markers (thyroglobulin plus anti-thyroglobulin antibodies) NICE NG230.

The 2025 American Thyroid Association (ATA) guidelines similarly recommend that ultrasound is the preferred imaging modality for follow-up of differentiated thyroid cancer, including papillary thyroid cancer (PTC), to assess the thyroid bed and cervical lymph nodes, with the timing based on risk and response to therapy Uludag et al. 2025. For intermediate-low risk patients, cervical ultrasound is advised within 6 to 12 months after completion of initial therapy to evaluate the thyroid bed and neck lymph nodes, then subsequent ultrasound frequency should be individualized depending on ongoing risk and response Uludag et al. 2025.

Ultrasound surveillance may be intensified if serum Tg or TgAb levels exceed 'excellent response' thresholds or if structural disease is detected. Conversely, in patients with excellent biochemical and structural response, ultrasound follow-up intervals may be extended or less frequent NICE NG230,Uludag et al. 2025.

Biochemical monitoring with serum thyroglobulin measurement is crucial during follow-up, typically every 3 to 6 months during the first two years, then every 6 to 12 months thereafter, correlating with ultrasound findings to tailor imaging frequency NICE NG230.

Thyrogen (recombinant human TSH) stimulation can be used to facilitate Tg measurement and improve sensitivity for detecting residual or recurrent disease in follow-up SmPC Thyrogen.

In summary, for intermediate-low risk PTC patients treated with surgery and RAI, the management includes: annual clinical visits, serum Tg and TgAb monitoring every 3–6 months initially and then spaced out; an initial neck ultrasound at 6 to 12 months post-treatment; and subsequent ultrasounds driven by biochemical or clinical findings rather than routine fixed-interval imaging NICE NG230,Uludag et al. 2025.